Compare TLX & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLX | BGSI |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | Australia | Canada |
| Employees | 1184 | 13449 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | TLX | BGSI |
|---|---|---|
| Price | $11.54 | $95.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $21.13 | ★ $157.00 |
| AVG Volume (30 Days) | ★ 208.5K | 21.8K |
| Earning Date | 08-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $35.07 |
| Revenue Next Year | N/A | $8.01 |
| P/E Ratio | ★ $150.33 | $231.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $88.97 |
| 52 Week High | $16.85 | $183.10 |
| Indicator | TLX | BGSI |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 44.42 |
| Support Level | $9.46 | $94.77 |
| Resistance Level | N/A | $99.16 |
| Average True Range (ATR) | 0.29 | 3.28 |
| MACD | 0.15 | 1.06 |
| Stochastic Oscillator | 72.53 | 69.76 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.